Abstract
In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Letters in Drug Design & Discovery
Title:Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores
Volume: 11 Issue: 3
Author(s): Maxime Meyer, Sandra Kuntz, Isabelle Grillier-Vuissoz, Helene Martin, Lysiane Richert, Stephane Flament, Yves Chapleur and Michel Boisbrun
Affiliation:
Keywords: Cancer, Chromane, Hepatotoxicity, Imidazole, Thiazolidine-2, 4-dione, Triazole, Troglitazone.
Abstract: In the course of our ongoing program dedicated to the synthesis of anti-proliferative compounds, we prepared new troglitazone derivatives bearing a biphenyle moiety. The chromane heterocycle was further replaced by imidazole and triazole derivatives. Many compounds exhibited fair to high activity towards various cancer cell lines. Among them, compound 17b reduced cell viability leading to only 22-34% viable cells in four cancer cell lines at 10 µM, but unfortunately also led to a low (13%) cell viability of non-malignant primary cultured human hepatocytes at 200 µM. Interestingly, compound 11b also reduced cell viability in colon and liver cancer cell lines (29% and 24% cell viability respectively at 10 µM), but maintained a high cell viability of non-malignant hepatocytes (reaching 71% cell viability at 200 µM), thus exhibiting a huge selectivity.
Export Options
About this article
Cite this article as:
Meyer Maxime, Kuntz Sandra, Grillier-Vuissoz Isabelle, Martin Helene, Richert Lysiane, Flament Stephane, Chapleur Yves and Boisbrun Michel, Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113106660080
DOI https://dx.doi.org/10.2174/15701808113106660080 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry Application of Sterylglucoside-Containing Particles for Drug Delivery
Current Pharmaceutical Biotechnology Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy
Anti-Cancer Agents in Medicinal Chemistry Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry Troika of the Mouse Blastocyst: Lineage Segregation and Stem Cells
Current Stem Cell Research & Therapy Current Status of Gene Therapy for Hepatocellular Carcinoma, with a Focus on Gene Delivery Approaches
Current Gene Therapy Prokaryotic Arsenate Reductase Enhances Arsenate Resistance in Mammalian Cells
Recent Patents on Food, Nutrition & Agriculture Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Current Cancer Drug Targets